Advantageous
Systems 
Advantageous Systems LLC (ADS) is a start-up medical device company
incorporating nanotechnology and biotechnology to revolutionize healthcare
by replacing conventional slow, painful, and often times unreliable
blood tests with a fast, reliable, and painless point-of-care diagnostic
device. The minimally-invasive diagnostic device invented by ADS does
not use needles or pinpricks and can diagnose a host of conditions,
such as blood glucose levels, HIV/AIDS, other viral and bacterial
infectious agents, and certain cancers and autoimmune diseases. Due
to its versatility and ease of use, the ADS diagnostic device has
the potential to become standard equipment in every hospital and the
glucose monitoring device of choice for many diabetics around the
globe who dislike the pain or anxiety of pinpricks and needles.
For more information contact: Adam Stein
Phone: 415-448-6266 • E-mail: adam@advantageoussystems.com
[Top
of Page]
Anergix
LLC 
Anergix LLC is an early phase biotechnology company developing a combined
cell/gene therapy treatment for multiple sclerosis, a disease that
affects roughly 400,000 Americans and 2.5 million people worldwide.
Our therapeutic strategy is to present immune regulatory cells with
low doses of the myelin peptide antigen thereby inducing immune tolerance
to the suspected myelin antigens thought to cause the autoimmune response.
To deliver these myelin peptides, Anergix sequesters proprietary peptide-secreting
cells in a small device implanted under the skin. Thus continuous,
low dose therapeutic levels of the peptide are generated on a systemic
basis – with excellent results in mouse models of the disease.
This approach has additional therapeutic applications to other autoimmune
diseases.
For more information contact: Katherine Louie, Ph.D. (CTO)
or David Graham (General Manager)
Phone: 626-840-1238 • E-mail: klouie@anergix4ms.com
or dgraham@anergix4ms.com
[Top
of Page]
BCN
Biosciences 
BCN Biosciences is an early phase biotechnology corporation with core
competencies in the oncology drug discovery market. BCN is currently
developing novel chemical entities that affect cellular proliferation
and cancer. BCN employs technology that can effectively mine novel
structures from natural resources, thus maximizing molecular diversity
for drug discovery. BCN is also focused on the development of therapeutic
agents against a novel epidermal growth factor gene target highly
expressed in tumor cells. Our experienced team of drug discovery and
oncology experts backs our commitment to developing novel and effective
medicines to prevent and treat cancer, one of world's most serious
diseases.
For more information contact: Andrew
J. Norris Ph.D. or Sudip Chakrabortty
Phone: 310-429-6760 • E-mail: contact@bcnbio.com
• Website: http://www.bcnbio.com
[Top
of Page]
Chimeric
Technologies 
Chimeric Technologies, Inc. is a service-based antibody firm specializing
in engineering of chimeric antibodies, polymeric antibodies, antibody
fusion proteins and combinations of those structures. Chimeric's team
of highly respected scientists has an extensive commercial and academic
background in cutting-edge antibody engineering. Chimeric provides
services to industry, government and academia. Chimeric Technologies'
first product is a novel diagnostic reagent for blood antigen typing.
Chimeric received a prestigious, highly competitive grant to develop
this technology. The Chimeric Technologies team has a virtually peerless
reputation for scientific accomplishment, creativity and integrity.
We provide a wide range of products and services to prestigious clients,
on time, on budget and with the highest possible degree of professionalism
and customer service.
For more information, visit: www.chimerictechnologies.com
[Top
of Page]
NeuBiogene,
Inc. 
NeuBiogene, Inc is a start-up corporation focused on the development
of molecular biological techniques and high quality products for research
scientists. The unique technologies and products developed by NeuBiogene
can help research scientists finish their designed experiments in
a cost-efficient and time-saving manner. NeuBiogene’s products
and proprietary technologies can be widely applied for DNA, RNA, protein,
and histology research. NeuBiogene is also developing new techniques
and tools for quick and efficient diagnosis and evaluation of the
sensitivity of cancer patients to chemotherapy. Our tools and diagnostics
kits can provide clinical doctors an efficient way to decide the best
therapy strategy for cancer patients.
For more information contact: Dr. Edwin Hu, Manager
Phone: 626-927-8477 • E-mail: zhongting@yahoo.com
[Top
of Page]
Neumedicines,
Inc. 
Neumedicines Inc. of Pasadena, California, is a preclinical-stage,
biopharmaceutical company focused on research and development of novel
protein therapeutics that treat and support patients suffering from
serious illnesses. The company's lead candidate, HemaMax (recombinant
human Interleukin-12, or rhIL-12), is a naturally-occurring signaling
molecule that acts at a basic level of the hematopoietic (blood-forming)
system by stimulating quiescent stem cells. In preclinical animal
models, HemaMax has shown the ability to generate robust and broad
hematopoietic recovery in lethally irradiated normal mice as well
as in tumor bearing mice treated with radiation and chemotherapy.
Neumedicines is currently advancing HemaMax as a treatment for chemotherapy-
and radiation-induced thrombocytopenia as well as for Acute Radiation
Syndrome.
Because HemaMax possesses both
potent hematological and immunological properties, it is uniquely
suitable as a hematological adjuvant cancer therapy acting to prevent
and alleviate three of the major side effects of cancer treatments,
namely anemia, neutropenia and thrombocytopenia.
In 2008, Neumedicines secured
a prestigious contract from the Biomedical Agency Radiation Medicine
Agency (BARDA) to develop Hemamax for the treatment of the Hematopoietic
Syndrome related to Acute Radiation Syndrome (ARS). The Company has
also has been awarded a small business grant (STTR) from National
Cancer Institute (NCI) for innovative cancer therapies to develop
HemaMax as a hematological adjuvant cancer therapy.
For more information
contact: Lena A. Basile, Ph.D., J.D., President, Chief Scientific
Officer
133 North Altadena Drive, #310, Pasadena, CA 91107
Phone: 818-606-2638 (cell) • 626-844-3810
(office) • E-mail: basile@neumedicines.com
[Top
of Page]
Ophidion,
Inc. 
Ophidion, Inc., an early-stage private biotechnology company developing
a new class of safe and effective drugs targeting some of the most
important receptors in the central nervous system. The activity of
this target is implicated in cognitive processes (important for the
alleviation of symptoms of, as examples, Schizophrenia, ADHD, and
Parkinson’s and Alzheimer’s disease), anxiety and depression,
pain, as well as many other important medical indications. Ophidion’s
licensed approach is to develop drugs that allosterically modulate
receptor activity by enhancing or reducing the activity of extracellular,
small accessory proteins. Allosteric drugs are predicted to enhance
or limit the receptors’ activity while preserving their spatio-temporal
activity patterns in the brain, and thereby significantly enhance
efficacy and reduce side effects. Ophidion’s approach is an
improvement over drugs that continuously activate or suppress these
receptors everywhere, thereby causing significant side effects, and
that over time cause receptor down-regulation and/or desensitization,
and hence loss of efficacy.
Based on the real unmet need
for more effective cognitive treatment not only for Alzheimer’s
disease patients, but also for the treatment of patients suffering
from other dementias, including age-associated memory impairment,
mild cognitive impairment, Parkinson’s disease, and vascular
dementia; from impaired cognitive abilities in other CNS disorders,
such as depression, ADHD, schizophrenia, and autism, and vascular
disorders, including hypertension, diabetes, and stroke; and for post-surgical
and chemotherapy patients, Ophidion will initially focus on the development
of cognitive enhancement drugs. Safer and more effective medication
for these population groups would expand the market for cognitive
drugs dramatically. Furthermore, the aging population represents additional,
enormous growth potential.
For more information
contact: Andreas Walz, Ph.D. • E-mail: andreas.walz@ophidionbio.com
[Top
of Page]
PLC
Diagnostics Inc. 
PLC Diagnostics, Inc (PLCD) is developing a novel, rapid diagnostic
testing platform for sensitive, robust, inexpensive and simple detection
of molecular biomarkers. This new platform is based on the company’s
novel microarray chip technology that replaces expensive laser scanning
with an intersecting grid of 100 mm-wide waveguides embedded in the
chip’s substrate. This technology enables real-time quantification
of molecular complex formation on the microarray surface without reagent
addition or wash steps, thereby significantly reducing assay complexity
and cost so that the platform can be used in point-of-care (POC) settings.
Our platform offers:
Diagnostics using 5 minutes
assay
Immunoassays and nucleic acids
Multiplexing (100 different assays)
Detection in complex matrices – Serum, whole Blood, Urine
etc.
Exquisite sensitivity – 1fM or better
Low cost – suitable for Point of Care
Robustness, compactness and ease of operation
For more information
contact: Reuven Duer, Ph.D. • E-mail: rduer@pleds.com
[Top
of Page]
Senju USA,
Inc. 
Established in April 2006, Senju USA, Inc is
working towards the development of new and exciting products . We're
a team of business development and clinical development members who
are working together with the same goal in sight---better products
for ophthalmic patients.
Email: contact@senju-usa.com
[Top
of Page]
Systine,
Inc. 
Systine provides a fundamentally new etching process and etch processing
tool set for precision, damage free etching of semiconductor materials
to enhance today’s leading edge 45nm production yields and to
meet the industry’s 32 nm and sub-32nm roadmap requirements.
Systine’s Low Energy Electron Enhance Etching (LE4) technology
utilizes a low energy, dc electron discharge and neutral chemical
etching species to drive a highly selective etching reaction that
has etched precision device features at dimensions of less than 20nm
with a surface finish that approaches atomic smoothness. This represents
a significant advance over traditional ion enhanced (dry) etching
which relies on momentum transfer by rf field accelerated reactive
ions to etch device features. While defining the device features,
this momentum transfer inflicts unavoidable material damage that degrades
semiconductor device yields and performance. Systine’s patented
damage-free LE4 technology breakthrough and the Gradina etching tools
based on it will play a major role in helping the semiconductor industry
meet the processing demands of extending Moore’s Law to the
ultimate limits at an atomic scale and to non-traditional device architectures.
Systine is positioned to become a leading supplier in the $4 billion
etch equipment market in 2011 and beyond..
For more information
contact: AH.P. (Pat) Gillis, Ph.D., CEO, CTO, Co-Founder
• E-mail: hpgillis@systineinc.com
[Top
of Page]
